Clinical trials: Colorectal Liver Metastasis
Metastatic Colorectal Cancer
Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
This study has two portions. The main goal of the Phase Ib portion of this research study is to see at what time Yttrium-90 (Y-90) radioembolization therapy and nivolumab can safely be given to patients without having too many…
- Trial name
- NCT03307603
- Testing
- yttrium-90 radioembolization, Phase Ib - nivolumab, Phase II - nivolumab
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer Liver Metastasis
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to…
- Trial name
- NCT06590259
- Testing
- Multi-mode tumor treatment system, Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 6th People's Hospital
Colorectal Liver Metastases
Preoperative Hepatic Arterial Infusion Chemotherapy
To assess the feasibility and results of liver resection after preoperative hepatic artery infusion (HAI) chemotherapy with FUDR.
- Trial name
- NCT00522509
- Testing
- Floxuridine FUDR
- Where
- Italy
- Sponsor
- IRCCS San Raffaele
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic).
- Conditions
- Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction
- Trial name
- NCT04221893
- Testing
- Radiation Therapy (RT)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.
- Trial name
- NCT05406206
- Testing
- Fruquintinib, Hepatic Arterial Infusion Chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
Cancer Colorectal
Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.
The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease.
- Trial name
- CETIDYL (NCT04189055)
- Testing
- Cetuximab, Irinotecan
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Hôpital Franco-Britannique-Fondation Cognacq-Jay
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Oligometastatic Disease, Liver Metastases
Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal…
- Conditions
- Oligometastatic Disease, Liver Metastases, Colorectal Cancer
- Trial name
- NCT04973007
- Testing
- Gadoxetate disodium, Gadobenate dimeglumine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Metastatic Colorectal Cancer
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
The goal of this study is to investigate the value of MR elastography-based SII as a means of detecting HGP noninvasively in patients with pathology-proven CRLM.
- Trial name
- NCT06208397
- Testing
- Magnetic Resonance Elastography and routine MRI
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Colorectal Cancer Liver Metastasis
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colorectal cancer patients with liver metastasis who have not received prior treatment.
- Trial name
- NCT06801665
- Testing
- FMT+QL1706+Bevacizumab+XELOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hua Jiang
Liver Transection During Laparoscopic Liver Resection
Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection
Background: until now, there is no agreement about the safest and feasible method for liver parenchyma transection during laparoscopic liver resection.
- Trial name
- LLS (NCT03208192)
- Testing
- liver transection during laparoscopic liver resection
- Where
- Russia
- Volunteers
- 68 people
- Sponsor
- Moscow Clinical Scientific Center
Colorectal Cancer, Liver Tumor
Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases
The aim of this study is to explore whether target therapy in combination with chemotherapy as treatment could improve survival or tumor response in patients undergoing Synchronic Hepatectomy for Colorectal Liver Metastases.
- Trial name
- NCT01677728
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xu jianmin
Colorectal Neoplasms
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
This study will include two parts: Phase I part is a dose-escalation study to assess the safety of increasing doses of TG6002 in combination with oral flucytosine (5-FC) in consecutive cohorts of 3 to 6 patients with colorectal…
- Trial name
- NCT04194034
- Testing
- TG6002, Flucytosine (5-FC)
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Transgene
Colorectal Cancer With Liver Metastasis
Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis
Objective: To evaluate the role of regional lymphadenectomy in patients with colorectal cancer liver metastasis. Background: Lymph node status is 1 of the most important prognostic factors in oncologic surgery; however, the role…
- Trial name
- LN (NCT01565811)
- Testing
- perihepatic lymphadenectomy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Gachon University Gil Medical Center
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol…
- Trial name
- ATOM (NCT01836653)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- EPS Corporation
Colorectal Cancer Liver Metastasis
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
- Trial name
- NCT06788171
- Testing
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy, Bevacizumab, Capecitabine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital